Close Menu

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.

The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.

The company's Q2 revenues came in above previously reported preliminary revenues of $835 million, but fell short of the analysts' estimate of $866.2 million.

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

Illumina is partnering with SV Health Investors, Sofinnova Partners, Seventure Partners, and F-Prime Capital to bring its startup incubator to Europe.

The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.

As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.

The suits, targeting products that include the BGISEQ-500 and MGISEQ-2000 platforms, add fuel to the ongoing patent dispute between the two firms.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.